| Trial ID: | L0384 |
| Source ID: | NCT04910178
|
| Associated Drug: |
Ursodeoxycholic acid
|
| Title: |
Evaluating the Effect of Pentoxifylline, Ursodiol, and Empagliflozin on Fatty Liver of Patients With Type-2 Diabetes
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Diabetes Type 2;NAFLD
|
| Interventions: |
Drug: Empagliflozin 25 MG;Drug: Ursodeoxycholic acid;Drug: Pentoxifylline 400 MG;Other: placebo
|
| Outcome Measures: |
liver fat content (percent);fatty liver staging (0, I, II, and III)Changes in Serum Gamma glutamyl transferase (?-GT);HbA1c (%);Fasting and 2-hr post-prandial serum glucose (mg/dl);Lipid profile;Changes in liver enzymes;Changes in direct and total bilirubin;Changes in total protein and albumin
|
| Sponsor/Collaborators: |
Asmaa Abdelfattah Elsayed
|
| Gender: |
All
|
| Age: |
18 Yearsnan
|
| Phases: |
Phase 4
|
| Enrollment: |
80
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).
|
| Start Date: |
25/05/2021
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
17 August 2021
|
| Locations: |
Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT04910178
|
